A review of poloxamer 407 pharmaceutical and pharmacological characteristics

Pharmaceutical Research

Volumn 23, Issue 12, 2006, Pages 2709-2728

  Dumortier, Gilles ^a   Grossiord, Jean Louis ^b   Agnely, Florence ^b   Chaumeil, Jean Claude ^a  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^b UNIV PARIS SUD   (France)

Author keywords

Adhesion; Copolymer; Gelation; Prolonged drug delivery; Rheology

Indexed keywords

ALGINIC ACID; BENZALKONIUM CHLORIDE; CARBOMER; CYANOCOBALAMIN; CYCLODEXTRIN; CYSTEINE; DANAZOL; DICLOFENAC; DOPA; EXCIPIENT; FLURBIPROFEN; INDOMETACIN; INSULIN; INTERLEUKIN 2; LIDOCAINE; LIPOSOME; MACROGOL; MORPHINE; NIFEDIPINE; PIROXICAM; POLOXAMER; POLYCAPROLACTONE; POLYCARBOPHIL; POLYETHYLENE; POLYGLACTIN; POVIDONE IODINE; SHORT CHAIN FATTY ACID; SODIUM CHLORIDE; SODIUM DIHYDROGEN PHOSPHATE; UNINDEXED DRUG;

ADHESION; BODY TEMPERATURE; CONTROLLED DRUG RELEASE; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG SOLUBILITY; FLOW KINETICS; GEL; GELATION; HUMAN; IMMUNOMODULATION; LIPID ANALYSIS; NANOPARTICLE; NEPHROTOXICITY; NONHUMAN; OSCILLATION; PHASE TRANSITION; PRIORITY JOURNAL; REVIEW; ROOM TEMPERATURE; SYSTEMATIC REVIEW;

EID: 33845351355     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9104-4     Document Type: Review

References (144)

1. E. Ruel-Gariepy and J. C. Leroux. In situ-forming hydrogels - review of temperature-sensitive systems. Eur. J. Pharm. Biopharm. 58(2):409-426 (2004).
2. A. A. Koffi, F. Agnely, G. Ponchel, and J. L. Grossiord. Modulation of the rheological and mucoadhesive properties of thermosensitive poloxamer-based hydrogels intended for the rectal administration of quinine. Eur. J. Pharm. Sci. 27(4):328-335 (2006).
3. G. Dumortier, N. El Kateb, M. Sahli, S. Kedjar, A. Boulliat, and J. C. Chaumeil. Development of a thermogelling ophthalmic formulation of cysteine. Drug Dev. Ind. Pharm. 32(1):63-72 (2006).
4. G. Dumortier, M. Zuber, N. Barges, F. Chast, H. Dutertre, and J. C. Chaumeil. Lacrimal and plasmatic kinetics of morphine after an ophthalmic delivery of three different formulations. Drug Dev. Ind. Pharm. 20(7):1147-1158 (1994).
5. R. Rowe, P. Sheskey, and S. Owen. Pharmaceutical Handbook of Pharmaceutical Excipients, 5th edn., Pharmaceutical, London UK and American Pharmaceutical Association, Washington, USA, 2005.
6. A. V. Kabanov, E. V. Batrakova, and V. Y. Alakhov. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J. Control. Release 82(2-3):189-212 (2002).
7. Z. Takats, K. Vekey, and L. Hegedus. Qualitative and quantitative determination of poloxamer surfactants by mass spectrometry. Rapid Commun. Mass Spectrom. 15(10):805-810 (2001).
8. S. M. Moghimi and A. C. Hunter. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol. 18(10):412-420 (2000).
9. G. Dumortier, J. L. Grossiord, M. Zuber, G. Couarraze, and J. C. Chaumeil. Thermoreversible morphine gel. Drug Dev. Ind. Pharm. 17(9):1255-1265 (1991).
10. J. Juhasz, V. Lenaerts, P. Raymond, and H. Ong. Diffusion of rat atrial natriuretic factor in thermoreversible poloxamer gels. Biomaterials 10(4):265-268 (1989).
11. T. Liu and B. Chu. Formation of homogeneous gel-like phases by mixed triblock copolymer micelles in aqueous solution: FCC to BCC phase transition. J. Appl. Cryst. 33:727-730 (2000).
12. T. Moore, S. Croy, S. Mallapragada, and N. Pandit. Experimental investigation and mathematical modeling of Pluronic F127 gel dissolution, drug release in stirred systems. J. Control. Release 67(2-3):191-202 (2000).
13. S. D. Desai and J. Blanchard. In vitro evaluation of pluronic F127-based controlled-release ocular delivery systems for pilocarpine. J. Pharm. Sci. 87(2):226-230 (1998).
14. E. Dimitrova, S. Bogdanova, M. Mitcheva, I. Tanev, and E. Minkov. Development of model aqueous ophthalmic solution of indomethacin. Drug Dev. Ind. Pharm. 26(12):1297-1301 (2000).
15. M. L. Veyries, G. Couarraze, S. Geiger, F. Agnely, L. Massias, B. Kunzli, and F. Faurisson. Controlled release of vancomycin from poloxamer 407 gels. Int. J. Pharm. 192(2):183-193 (1999).
16. W. Saski and S. G. Shah. Availability of drug in the presence of surface active agents. I. Critical micelle concentration of some oxyethylene- oxypropylene polymers. J. Pharm. Sci. 54:71-74 (1965).
17. K. Huang, B. P. Lee, D. R. Ingram, and P. B. Messersmith. Synthesis and characterization of self-assembling block copolymers containing bioadhesive end groups. Biomacromolecules 3(2):397-406 (2002).
18. N. Pandit, T. Trygstad, S. Croy, M. Bohorquez, and C. Koch. Effect of salts on the micellization, clouding, and solubilization behavior of Pluronic F127 solutions. J. Colloid Interface Sci. 222(2):213-220 (2000).
19. J. A. Anderson. Micelle formation by oxyethylene-oxypropylene polymers. Pharm. Acta Helv. 47:304-308 (1972).
20. D. Attwood, J. H. Collett, and C. J. Tait. The micellar properties of the poly(oxyethylene)-poly(oxypropylene) copolymer Pluronic F 127 in water and electrolyte solution. Int. J. Pharm. 26:25-33 (1985).
21. M. Bohorquez, C. Koch, T. Trygstad, and N. Pandit. A study of the temperature-dependent micellization of Pluronic F127. J. Colloid Interface Sci. 216(1):34-40 (1999).
22. C. McDonald and C. K. Wong. The effect of temperature on the micellar properties of a polyoxyethylene-polyoxypropylene polymer in water. J. Pharm. Pharmacol. 26:556-557 (1974).
23. C. McDonald and C. K. Wong. Surface tension and light scattering studies on polyoxyethylene-polyoxypropylene copolymers in water. Aust. J. Pharm. Sci. 6:85-89 (1977).
24. J. M. Barichello, M. Morishita, K. Takayama, Y. Chiba, S. Tokiwa, and T. Nagai. Enhanced rectal absorption of insulin-loaded Pluronic F-127 gels containing unsaturated fatty acids. Int. J. Pharm. 183(2):125-132 (1999).
25. J. M. Barichello, M. Morishita, K. Takayama, and T. Nagai. Absorption of insulin from pluronic F-127 gels following subcutaneous administration in rats. Int. J. Pharm. 184(2):189-198 (1999).
26. R. G. Strickley. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21(2):201-230 (2004).
27. S. C. Shin and C. W. Cho. Physicochemical characterizations of piroxicam-poloxamer solid dispersion. Pharm. Dev. Technol. 2(4):403-407 (1997).
28. S. Chutimaworapan, G. C. Ritthidej, E. Yonemochi, T. Oguchi, and K. Yamamoto. Effect of water-soluble carriers on dissolution characteristics of nifedipine solid dispersions. Drug Dev. Ind. Pharm. 26(11):1141-1150 (2000).
29. C. Rouchotas, O. E. Cassidy, and G. Rowley. Comparison of surface modification and solid dispersion techniques for drug dissolution. Int. J. Pharm. 195(1-2):1-6 (2000).
30. T. L. Rogers, K. P. Johnston, and R. O. Williams. Physical stability of micronized powders produced by spray-freezing into liquid (SFL) to enhance the dissolution of an insoluble. Drug Pharm. Dev. Technol. 8(2):187-197 (2003).
31. T. L. Rogers, A. C. Nelsen, M. Sarkari, T. J. Young, K. P. Johnston, and R. O. Williams. Enhanced aqueous dissolution of a poorly water soluble drug by novel particle engineering technology, spray-freezing into liquid with atmospheric freeze-drying. Pharm. Res. 20(3):485-493 (2003).
32. T. L. Rogers, K. A. Overhoff, P. Shah, P. Santiago, M. J. Yacaman, K. P. Johnston, and R. O. Williams. Micronized powders of a poorly water soluble drug produced by a spray-freezing into liquid-emulsion process. Eur. J. Pharm. Biopharm. 55(2):161-172 (2003).
33. M. L. Veyries, F. Faurisson, M. L. Joly-Guillou, and B. Rouveix. Control of staphylococcal adhesion to polymethylmethacrylate and enhancement of susceptibility to antibiotics by poloxamer 407. Antimicrob. Agents Chemother.44(4):1093-1096 (2000).
34. P. Gilbert, M. V. Jones, D. G. Allison, S. Heys, T. Maira, and P. Wood. The use of poloxamer hydrogels for the assessment of biofilm susceptibility towards biocide treatments. J. Appl. Microbiol. 85(6):985-990 (1998).
35. J. Juhasz, V. Lenaerts, D. Raymond, and O. Huy. Diffusion of natirel factor in thermoreversible poloxamer gels. Biomaterials 2:365-369 (1986).
36. E. A. Pec, Z. G. Wout, and T. P. Johnston. Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat. J. Pharm. Sci. 81(7):626-630 (1992).
37. P. L. Wang and T. P. Johnston. Enhanced stability of two model proteins in an agitated solution environment using poloxamer 407. J. Parenter. Sci. Technol. 47(4):183-189 (1993).
38. L. E. Bromberg. Interactions among proteins and hydrophobically modified polyelectrolytes. J. Pharm. Pharmacol. 53(4):541-547 (2001).
39. M. Katakam and A. K. Banga. Use of poloxamer polymers to stabilize recombinant human growth hormone against various processing stresses. Pharm. Dev. Technol. 2(2):143-149 (1997).
40. L. P. Stratton, A. Dong, M. C. Manning, and J. F. Carpenter. Drug delivery matrix containing native protein precipitates suspended in a poloxamer gel. J. Pharm. Sci. 86(9):1006-1010 (1997).
41. W. J. Lin and L. I. Huang. Influence of pluronics on protein-loaded poly(epsilon-caprolactone) microparticles. J. Microencapsul. 18(2):191-197 (2001).
42. C. Sturesson and J. Carlfors. Incorporation of protein in PLG-microspheres with retention of bioactivity. J. Control. Release 67(2-3):171-178 (2000).
43. M. C. Woodle, M. S. Newman, and F. J. Martin. Liposome leakage and blood circulation, comparison of adsorbed block copolymers with covalent attachment of PEG. Int. J. Pharm. 88:327-334 (1992).
44. J. D. Castile and K. M. Taylor. Factors affecting the size distribution of liposomes produced by freeze-thaw extrusion. Int. J. Pharm. 188(1):87-95 (1999).
45. J. D. Castile, K. M. Taylor, and G. Buckton. A high sensitivity differential scanning calorimetry study of the interaction between poloxamers and dimyristoylphosphatidylcholine and dipalmitoylphosphatidylcholine liposomes. Int. J. Pharm. 182(1):101-110 (1999).
46. J. D. Castile, K. M. Taylor, and G. Buckton. The influence of incubation temperature and surfactant concentration on the interaction between dimyristoylphosphatidylcholine liposomes and poloxamer surfactants. Int. J. Pharm. 221(1-2):197-209 (2001).
47. P. Chandaroy, A. Sen, P. Alexandridis, and S. W. Hui. Utilizing temperature-sensitive association of Pluronic F-127 with lipid bilayers to control liposome-cell adhesion. Biochim. Biophys. Acta 1559(1):32-42 (2002).
48. L. Olivieri, M. Seiller, L. Bromberg, M. Besnard, T. N. Duong, and J. L. Grossiord. Optimization of a thermally reversible W/O/W multiple emulsion for shear-induced drug release. J. Control. Release 88(3):401-412 (2003).
49. C. Charrueau, C. Tuleu, V. Astre, J. L. Grossiord, and J. C. Chaumeil. Poloxamer 407 as a thermogelling and adhesive polymer for rectal administration of short-chain fatty acids. Drug Dev. Ind. Pharm. 27(4):351-357 (2001).
50. C. S. Yong, J. Choi, Q. Z. Quan, J. D. Rhee, C. K. Kim, S. J. Lim, K. M. Kim, P. S. Oh, and H. G. Choi. Effect of sodium chloride on the gelation temperature, gel strength and bioadhesive force of poloxamer gels containing diclofenac sodium. Int. J. Pharm. 226(1-2):195-205 (2001).
51. J. M. Ryu, S. J. Chung, M. H. Lee, C. K. Kim, and C. K. Shim. Increased bioavailability of propranolol in rats by retaining thermally gelling liquid suppositories in the rectum. J. Control. Release 59(2):163-172 (1999).
52. H. Choi, M. Lee, M. Kim, and C Kim. Effect of additives on the physicochemical properties of liquid suppository bases. Int. J. Pharm. 190(1):13-19 (1999).
53. A. M. Le Ray, P. Iooss, A. Gouyette, V. Vonarx, T. Patrice, and C. Merle. Development of a "continuous-flow adhesion cell" for the assessment of hydrogel adhesion. Drug Dev. Ind. Pharm. 25(8):897-904 (1999).
54. E. Y. Kim, Z. G. Gao, J. S. Park, H. Li, and K. Han. rhEGF/HP-beta-CD complex in poloxamer gel for ophthalmic delivery. Int. J. Pharm. 233(1-2):159-167 (2002).
55. L. Bourre, S. Thibaut, A. Briffaud, Y. Lajat, and T. Patrice. Potential efficacy of a delta 5-aminolevulinic acid thermosetting gel formulation for use in photodynamic therapy of lesions of the gastrointestinal tract. Pharmacol. Res. 45(2): 159-165 (2002).
56. S. S. Pisal, A. R. Paradkar, K. R. Mahadik, and S. S. Kadam. Pluronic gels for nasal delivery of Vitamin B12. Part I, preformulation study. Int. J. Pharm. 270(1-2):37-45 (2004).
57. J. C. Gilbert, J. L. Richarson, M. C. Davies, and K. J. Palin. The effect of solutes and polymers on the gelation properties of Puronic F-127 solutions for controlled drug delivery. J. Control. Release 5:113-118 (1987).
58. J. Y. Chang, Y. K. Oh, H. G. Choi, Y. B. Kim, and C. K. Kim. Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in physiological conditions. Int. J. Pharm. 241(1):155-163 (2002).
59. A. Shawesh, S. Kallioinen, O. Antikainen, and J. Yliruusi. Influence of storage time and temperature on the stability of indomethacin Pluronic F-127 gels. Pharmazie 57(10):690-694 (2002).
60. S. C. Chi and H. W. Jun. Anti-inflammatory activity of ketoprofen gel on carrageenan-induced paw edema in rats. J. Pharm. Sci. 79:974-977 (1990).
61. S. C. Chi and H. W. Jun. Release rates of ketoprofen from poloxamer gels in a membraneless diffusion cell. J. Pharm. Sci. 80(3):280-283 (1991).
62. S. C. Miller and B. R. Drabik. Rheological properties of poloxamer vehicles. Int. J. Pharm. 18:269-276 (1984).
63. V. Lenaerts, C. Triqueneaux, M. Quarton, F. Rieg-Falson, and P. Couvreur. Temperature-dependant rheological behavior of Puronic F-127 aqueous solutions. Int. J. Pharm. 39:121-127 (1987).
64. K. Edsman, J. Carlfors, and R. Petersson. Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur. J. Pharm. Sci. 6(2):105-112 (1998).
65. G. Wei, H. Xu, P. T. Ding, S. M. Li, and J. M. Zheng. Thermosetting gels with modulated gelation temperature for ophthalmic use, the rheological and gamma scintigraphic studies. J. Control. Release 83(1):65-74 (2002).
66. E. J. Ricci, M. V. Bentley, M. Farah, R. E. Bretas, and J. M. Marchetti. Rheological characterization of Poloxamer 407 l idocaine hydrochloride gels. Eur. J. Pharm. Sci. 17(3):161-167 (2002).
67. A. Cabana, A. Aït-Kadi, and J. Juhász. Study of the gelation process of polyethylene oxidea-polypropylene oxideb- polyethylene oxidea (poloxamer 407) aqueous solutions. J. Colloid Interface Sci. 190:307-312 (1997).
68. R. Bhardwaj and J. Blanchard. Controlled-release delivery system for the alpha-MSH analog melanotan-I using poloxamer 407. J. Pharm. Sci. 85(9):915-919 (1996).
69. Y. J. Park, C. S. Yong, H. M. Kim, J. D. Rhee, Y. K. Oh, C. K. Kim, and H. G. Choi. Effect of sodium chloride on the release, absorption and safety of diclofenac sodium delivered by poloxamer gel. Int. J. Pharm. 263(1-2):105-111 (2003).
70. A. M. El Gendy, H. W. Jun, and A. A. Kassem. In vitro release studies of flurbiprofen from different topical formulations. Drug Dev. Ind. Pharm. 28(7):823-831 (2002).
71. A. Paavola, I. Kilpelainen, J. Yliruusi, and P. Rosenberg. Controlled release injectable liposomal gel of ibuprofen for epidural analgesia. Int. J. Pharm. 199(1):85-93 (2000).
72. A. Takahashi, S. Suzuki, N. Kawasaki, W. Kubo, S. Miyazaki, R. Loebenberg, J. Bachynsky, and D. Attwood. Percutaneous absorption of non-steroidal anti-inflammatory drugs from in situ gelling xyloglucan formulations in rats. Int. J. Pharm. 246(1-2):179-186 (2002).
73. T. P. Johnston, M. A. Punjabi, and C. J. Froelich. Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice. Pharm. Res. 9(3):425-434 (1992).
74. M. Morishita, J. M. Barichello, K. Takayama, Y. Chiba, S. Tokiwa, and T. Nagai. Pluronic F-127 gels incorporating highly purified unsaturated fatty acids for buccal delivery of insulin. Int. J. Pharm. 212(2):289-293 (2001).
75. S. Proniuk, S. E. Dixon, and J. Blanchard. Investigation of the utility of an in vitro release test for optimizing semisolid dosage forms. J. Pharm. Dev. Technol. 6(3):469-476 (2001).
76. A. Paavola, J. Yliruusi, Y. Kajimoto, E. Kalso, T. Wahlstrom, and P. Rosenberg. Controlled release of lidocaine from injectable gels and efficacy in rat sciatic nerve block. Pharm. Res. 12(12):1997-2002 (1995).
77. P. C. Chen, D. S. Kohane, Y. J. Park, R. H. Bartlett, R. Langer, and V. C. Yang. Injectable microparticle-gel system for prolonged and localized lidocaine release II. In vivo anesthetic effects. J. Biomed. Mater. Res. 70A(3):459-466 (2004).
78. E. J. Ricci, L. O. Lunardi, D. M. Nanclares, and J. M. Marchetti. Sustained release of lidocaine from Poloxamer 407 gels. Int. J. Pharm. 288(2):235-244 (2005).
79. T. Abe, M. Sasaki, H. Nakajima, M. Ogita, H. Naitou, A. Nagase, K. Taguchi, and S. Miyazaki. Evaluation of pluronic F127 as a base for gradual release of anticancer drug. Gan To Kagaku Ryoho 17(8):1546-1550 (1990).
80. A. Bochot, E. Fattal, A. Gulik, G. Couarraze, and P. Couvreur. Liposomes dispersed within a thermosensitive gel, a new dosage form for ocular delivery of oligonucleotides. Pharm. Res. 15(9):1364-1369 (1998).
81. M. M. Amiji, P. K. Lai, D. B. Shenoy, and M. Rao. Intratumoral administration of paclitaxel in an in situ gelling poloxamer 407 formulation. Pharm. Dev. Technol. 7(2):195-202 (2002).
82. S. D. Desai and J. Blanchard. Evaluation of pluronic F127-based sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model. J. Pharm. Sci. 87(10):1190-1195 (1998).
83. S. Miyazaki, S. Suzuki, N. Kawasaki, K. Endo, A. Takahashi, and D. Attwood. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int. J. Pharm. 229(1-2):29-36 (2001).
84. S. C. Shin, C. W. Cho, and H. K. Choi. Permeation of piroxicam from the poloxamer gels. Drug Dev. Ind. Pharm. 25(3):273-278 (1999).
85. F. Fawaz, A. Koffi, M. Guyot, and P. Millet. Comparative in vitro-in vivo study of two quinine rectal gel formulations. Int. J. Pharm. 280(1-2):151-162 (2004).
86. A. H. El-Kamel. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int. J. Pharm. 241(1):47-55 (2002).
87. S. C. Shin and J. Y. Kim. Enhanced permeation of triamcinolone acetonide through the buccal mucosa. Eur. J. Pharm. Biopharm. 50(2):217-220 (2000).
88. K. A. Fults and T. P. Johnston. Sustained-release of urease from a poloxamer gel matrix. J. Parenter. Sci. Technol. 44(2):58-65 (1990).
89. B. C. Anderson, N. K. Pandit, and S. K. Mallapragada. Understanding drug release from poly(ethylene oxide)-b-poly (propylene oxide)-b-poly(ethylene oxide) gels. J. Control. Release 70(1-2):157-167 (2001).
90. X. Xu and P. I. Lee. Programmable drug delivery from an erodible association polymer system. Pharm. Res. 10(8):1144-1152 (1993).
91. Y. Mao, M. J. Thompson, Q. Wang, and E. W. Tsai. Quantitation of poloxamers in pharmaceutical formulations using size exclusion chromatography and colorimetric methods. J. Pharm. Biomed. Anal. 35(5):1127-1142 (2004).
92. S. C. Shin, E. Y. Shin, and C. W. Cho. Enhancing effects of fatty acids on piroxicam permeation through rat skins. Drug Dev. Ind. Pharm. 26(5):563-566 (2000).
93. S. C. Shin, C. W. Cho, and I. J. Oh. Effects of non-ionic surfactants as permeation enhancers towards piroxicam from the poloxamer gel through rat skins. Int. J. Pharm. 222(2):199-203 (2001).
94. S. C. Shin, J. Y. Kim, and I. J. Oh. Mucoadhesive and physicochemical characterization of Carbopol-Poloxamer gels containing triamcinolone acetonide. Drug Dev. Ind. Pharm. 26(3):307-312 (2000).
95. P. Chetoni, L. Panichi, S. Burgalassi, U. Benelli, and M. F. Saettone. Pharmacokinetics and anti-inflammatory activity in rabbits of a novel indomethacin ophthalmic solution. J. Ocular Pharmacol. Ther. 16(4):363-372 (2000).
96. J. W. Kwon, Y. K. Han, W. J. Lee, C. S. Cho, S. J. Paik, D. I. Cho, J. H. Lee, and W.R. Wee. Biocompatibility of poloxamer hydrogel as an injectable intraocular lens: a pilot study. J. Cataract Refract. Surg. 31(3):607-613 (2005).
97. I. Pepic, N. Jalsenjak, and I. Jalsenjak. Micellar solutions of triblock copolymer surfactants with pilocarpine. Int. J. Pharm. 272(1-2):57-64 (2004).
98. S. D. Desai and J. Blanchard. Pluronic F127-based ocular delivery system containing biodegradable polyisobutylcyanoacrylate nanocapsules of pilocarpine. Drug Deliv. 7(4):201-207 (2000).
99. R. M. Nalbandian, R. L. Henry, and H. S. Wilks. Artificial skin II. Pluronic F-127 silver nitrate or silver lactate gel in the treatment of thermal burns. J. Biomed. Mater. Res. 6:583-590 (1972).
100. L. H. Marsh, C. Alexander, M. Coke, P. W. Dettmar, M. Havler, T. G. Nevell, J. D. Smart, B. Timmins, and J. Tsibouklis. Adsorbed pluronics on the skin of human volunteers, effects on bacterial adhesion. Int. J. Pharm. 251(1-2): 155-163 (2003).
101. S. Miyazaki, T. Tobiyama, M. Takada, and D. Attwood. Percutaneous absorption of indomethacin from pluronic F127 gels in rats. J. Pharm. Pharmacol. 47(6):455-457 (1995).
102. S. Shin, C. Cho, and I. Oh. Enhanced efficacy by percutaneous absorption of piroxicam from the poloxamer gel in rats. Int. J. Pharm. 193(2):213-218 (2002).
103. H. Suh, H. W. Jun, M. T. Dzimianski, and G. W. Lu. Pharmacokinetic and local tissue disposition studies of naproxen - following topical and systemic administration in dogs and rats. Biopharm. Drug Dispos. 18(7):623-633 (1997).
104. G. W. Lu, H. W. Jun, M. T. Dzimianski, H. C. Qiu, and J. W. McCall. Pharmacokinetic studies of methotrexate in plasma and synovial fluid following i.v. bolus and topical routes of administration in dogs. Pharm. Res. 12(10):1474-1477 (1995).
105. A. F. El-Kattan, C. S. Asbill, N. Kim, and B. B. Michniak. Effect of formulation variables on the percutaneous permeation of ketoprofen from gel formulations. Drug Deliv. 7(3):147-153 (2000).
106. P. Wuthrich, M. Martenet, and P. Buri. Effect of formulation additives upon the intranasal bioavailability of a peptide drug, tetracosactide (ACTH1-24). Pharm. Res. 11(2):278-282 (1994).
107. J. G. Wenzel, K. S. Balaji, K. Koushik, C. Navarre, S. Duran, C. H. Rahe, and U. B. Kompella. Pluronic F127 gel formulations of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle. J. Control. Release 85(1-3): 51-59 (2002).
108. A. B. Saim, Y. Cao, Y. Weng, C. N. Chang, M. A. Vacanti, C. A. Vacanti, and R. D. Eavey. Engineering autogenous cartilage in the shape of a helix using an injectable hydrogel scaffold. Laryngoscope 110(10):1694-1697 (2000).
109. Y. Wang, S. Liu, C. Y. Li, and F. Yuan. A novel method for viral gene delivery in solid tumors. Cancer Res. 65(17):7541-7545 (2005).
110. S. N. Robinson, J. M. Chavez, J. M. Blonder, V. M. Pisarev, R. L. Mosley, H. Sang, G. J. Rosenthal, and J. E. Talmadge. Hematopoietic progenitor cell mobilization in mice by sustained delivery of granulocyte colony-stimulating factor. J. Interferon Cytokine Res. 25(8):490-500 (2005).
111. J. Raymond, A. Metcalfe, I. Salazkin, and A. Schwarz. Temporary vascular occlusion with poloxamer 407. Biomaterials 25(18):3983-3989 (2004).
112. M. Varshney, T. E. Morey, D. O. Shah, J. A. Flint, B. M. Moudgil, C. N. Seubert, and D. M. Dennis. Pluronic microemulsions as nanoreservoirs for extraction of bupivacaine from normal saline. J. Am. Chem. Soc. 126(16):5108-5112 (2004).
113. E. B. Fowler, M. F. Cuenin, S. D. Hokett, M. E. Peacock, J. C. McPherson, T. R. Dirksen, M. Sharawy, and M. A. Billman. Evaluation of pluronic polyols as carriers for grafting materials, study in rat calvaria defects. J. Periodontol.73(2):191-197 (2002).
114. C. M. Clokie and M. R. Urist. Bone morphogenetic protein excipients, comparative observations on poloxamer. Plast. Reconstr. Surg. 105(2):628-637 (2000).
115. C. A. Arevalo-Silva, R. D. Eavey, Y. Cao, M. Vacanti, Y. Weng, and C. A. Vacanti. Internal support of tissue-engineered cartilage. Arch. Otolaryngol. Head Neck Surg. 126(12):1448-1452 (2000).
116. S. D. Hokett, M. F. Cuenin, R. B. O'Neal, W. A. Brennan, S. L. Strong, R. R. Runner, J. C. McPherson, and T. E. Van Dyke. Pluronic polyol effects on human gingival fibroblast attachment and growth. J. Periodontol. 71(5):803-809 (2000).
117. M. A. Westerink, S. L. Smithson, N. Srivastava, J. Blonder, C. Coeshott, and G. J. Rosenthal. ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid. Vaccine 20(5-6):711-723 (2001).
118. A. V. Kabanov, P. Lemieux, S. Vinogradov, and V. Alakhov. Pluronic block copolymers, novel functional molecules for gene therapy. Adv. Drug Deliv. Rev. 54(2):223-233 (2002).
119. C. W. Cho, Y. S. Cho, B. T. Kang, J. S. Hwang, S. N. Park, and D. Y. Yoon. Improvement of gene transfer to cervical cancer cell lines using non-viral agents. Cancer Lett. 162(1):75-85 (2001).
120. S. M. Moghimi. Re-establishing the long circulatory behaviour of poloxamine-coated particles after repeated intravenous administration, applications in cancer drug delivery and imaging. Biochim. Biophys. Acta 1472(1-2):399-403 (1999).
121. S. M. Moghimi. Modulation of lymphatic distribution of subcutaneously injected poloxamer 407-coated nanospheres. FEBS Lett. 540(1-3):241-244 (2003).
122. S. Stolnik, B. Daudali, A. Arien, J. Whetstone, C. R. Heald, M. Garnett, S. S. Davis, and L. Illum. The effect of surface coverage and conformation of poly(ethylene oxide) (PEO) chains of poloxamer 407 on the biological fate of model colloidal drug carriers. Biochim. Biophys. Acta 1514(2):261-279 (2001).
123. C. J. Porter, S. M. Moghimi, L. Illum, and S. S. Davis. The polyoxyethylene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett. 305(1):62-66 (1992).
124. J. Lode, I. Fichtner, J. Kreuter, A. Berndt, J. E. Diederichs, and R. Reszka. Influence of surface-modifying surfactants on the pharmacokinetic behavior of 14C-poly (methylmethacrylate) nanoparticles in experimental tumor models. Pharm. Res. 18(11):1613-1619 (2001).
125. H. M. Redhead, S. S. Davis, and L. Illum. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908, in vitro characterisation and in vivo evaluation. J. Control. Release 70(3):353-363 (2001).
126. J. K. Jackson, C. M. Springate, W. L. Hunter, and H. M. Burt. Neutrophil activation by plasma opsonized polymeric microspheres, inhibitory effect of pluronic F127. Biomaterials 21(14):1483-1491 (2000).
127. P. Lemieux, N. Guerin, G. Paradis, R. Proulx, L. Chistyakova, A. Kabanov, and V. Alakhov. A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle. Gene Ther. 7(11):986-991 (2000).
128. S. Danson, D. Ferry, V. Alakhov, J. Margison, D. Kerr, D. Jowle, M. Brampton, G. Halbert, and M. Ranson. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer 90(11):2085-2091 (2004).
129. C. Li, W. K. Palmer, and T. P. Johnston. Disposition of poloxamer 407 in rats following a single intraperitoneal injection assessed using a simplified colorimetric assay. J. Pharm. Biomed. Anal. 14(5):659-665 (1996).
130. T. P. Johnston and W. K. Palmer. Effect of poloxamer 407 on the activity ofmicrosomal 3-hydroxy-3-methylglutaryl CoA reductase in rats. J. Cardiovasc. Pharmacol. 29(5):580-585 (1997).
131. T. P. Johnston, J. Baker, A. S. Jamal, D. Hall, E. E. Emeson, and W. K. Palmer. Potential downregulation of HMG-CoA reductase after prolonged administration of P-407 in C57BL/6 mice. J. Cardiovasc. Pharmacol. 34(6):831-842 (1999).
132. T. P. Johnston, J. C. Baker, D. Hall, S. Jamal, W. K. Palmer, and E. E. Emeson. Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin. Atherosclerosis 149(2):303-313 (2000).
133. T. P. Johnston, L. B. Nguyen, W. A. Chu, and S. Shefer. Potency of select statin drugs in a new mouse model of hyperlipidemia and atherosclerosis. Int. J. Pharm. 229(1-2):75-86 (2001).
134. T. P. Johnston, J. W. Coker, B. J. Paigen, and O. Tawfik. Sex does not seem to influence the formation of aortic lesions in the P-407-induced mouse model of hyperlipidemia and atherosclerosis. J. Cardiovasc. Pharmacol. 39(3):404-411 (2002).
135. W. K. Palmer, E. E. Emeson, and T. P. Johnston. The poloxamer 407-induced hyperlipidemic atherogenic animal model. Med. Sci. Sports Exerc. 29(11):1416-1421 (1997).
136. W. K. Palmer, E. E. Emeson, and T. P. Johnston. Poloxamer 407-induced atherogenesis in the C57BL/6 mouse. Atherosclerosis 136(1):115-123 (1998).
137. D. R. Brocks and K. M. Wasan. The influence of lipids on stereoselective pharmacokinetics of halofantrine: important implications in food-effect studies involving drugs that bind to lipoproteins. J. Pharm. Sci. 91(8):1817-1826 (2002).
138. R. J. Ramirez, J. Novak, T. P. Johnston, R. E. Gandley, M. K. McLaughlin, and C. A. Hubel. Endothelial function and myogenic reactivity in small mesenteric arteries of hyperlipidemic pregnant rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281(4):R1330-R1337 (2001).
139. J. M. Blonder, L. Baird, J. C. Fulfs, and G. J. Rosenthal. Dose-dependent hyperlipidemia in rabbits following administration of poloxamer 407 gel. Life Sci. 65(21):PL261-PL266 (1999).
140. L. A. Eliot, R. T. Foster, and F. Jamali. Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat. Pharm. Res. 16(2):309-313 (1999).
141. L. A. Eliot and F. Jamali. Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats. J. Pharmacol. Exp. Ther. 291(1):188-193 (1999).
142. T. P. Johnston, H. Beris, and J. L. Kennedy. Effects on splenic, hepatic, hematological, and growth parameters following highdose poloxamer 407 administration to rats. Int. J. Pharm. 100:279-284 (1993).
143. T. P. Johnston and S. C. Miller. Toxicological evaluation of poloxamer vehicles for intra-muscular use. J. Parenter. Sci. Tech. 39:83-88 (1985).
144. T. P. Johnston and S. C. Miller. Inulin disposition following intramuscular administration of an inulin/poloxamer gel matrix. J. Parenter. Sci. Technol. 43(6):279-286 (1989).